Importantly, our results revealed that loss of membranous E‐cadherin localization is associated with poor response to SSAs in acromegaly patients, in line with a previous study.14 IGF1 reduction after 3 and 6 months of SSAs treatment was markedly lower in GH‐secreting tumours with E‐cadherin IHC score 1 compared to tumours with scores 2 and 3. This evidence concerns the gene GH1 and acromegaly.